Proportion of inflammatory bowel diseases patients with suboptimal disease control in daily clinical...

Area of Science:

• Gastroenterology
• Immunology
• Clinical Research

Background:

• Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis (UC), are chronic conditions causing progressive intestinal damage.
• Current treatments for IBD have limited efficacy, leading to suboptimal disease management and a substantial patient burden.

Purpose of the Study:

• To estimate the prevalence of suboptimal disease control (SDC) in Crohn's disease and UC patients within a real-world setting.
• To identify factors contributing to SDC and assess opportunities for treatment optimization.

Main Methods:

• A non-interventional, cross-sectional study (IBD-PODCAST) was conducted across 103 sites in 10 countries.
• Criteria for SDC were based on STRIDE-II guidelines, adapted by an expert panel.
• 2185 patients (1108 Crohn's disease, 1077 UC) were included, with data collected on disease characteristics, treatment, and SDC indicators.

Main Results:

• SDC was identified in 52.2% of Crohn's disease patients and 44.3% of UC patients.
• Primary drivers of SDC included impaired quality of life, extraintestinal manifestations, steroid overuse, and active inflammation.
• Treatment optimization opportunities were noted in 49% of Crohn's disease and 61% of UC patients on advanced therapies.

Conclusions:

• A high proportion of IBD patients experience SDC, indicating a significant unmet medical need globally.
• Focusing on monitoring and addressing SDC is crucial for improving patient outcomes and quality of life in IBD.
• Further analysis should explore strategies for responding to SDC and enhancing patients' quality of life.